Researchers developed a PEGylated version of thymosin beta 4 (PEG-rTB4) to overcome drugability challenges that have prevented TB4 approval despite 10+ years of clinical trials for MI, ulcers, and dry eye. The modified compound showed superior stability, longer circulation time, and demonstrated efficacy in treating myocardial infarction by reducing cardiac remodeling, restoring function, and promoting tissue repair via the Akt/Bcl-2/caspase-3 pathway. This represents a formulation advancement strategy that could inform development of TB4-Fragment products for practitioner use.
For your business
PEGylation improved TB4 stability and circulation time in MI models, supporting formulation strategies relevant to TB4-Fragment development.